Department of Nephrology, University Medical Center Groningen, Groningen, Netherlands.
Univ. Grenoble Alpes, CNRS, CEA, IBS, Grenoble, France.
Front Immunol. 2020 Apr 28;11:732. doi: 10.3389/fimmu.2020.00732. eCollection 2020.
It is well-known that heparin and other glycosaminoglycans (GAGs) inhibit complement activation. It is however not known whether fractionation and/or modification of GAGs might deliver pathway-specific inhibition of the complement system. Therefore, we evaluated a library of GAGs and their derivatives for their functional pathway specific complement inhibition, including the MASP-specific C4 deposition assay. Interaction of human MASP-2 with heparan sulfate/heparin was evaluated by surface plasmon resonance, ELISA and in renal tissue. pathway-specific complement assays showed that highly sulfated GAGs inhibited all three pathways of complement. Small heparin- and heparan sulfate-derived oligosaccharides were selective inhibitors of the lectin pathway (LP). These small oligosaccharides showed identical inhibition of the ficolin-3 mediated LP activation, failed to inhibit the binding of MBL to mannan, but inhibited C4 cleavage by MASPs. Hexa- and pentasulfated tetrasaccharides represent the smallest MASP inhibitors both in the functional LP assay as well in the MASP-mediated C4 assay. Surface plasmon resonance showed MASP-2 binding with heparin and heparan sulfate, revealing high Kon and Koff rates resulted in a Kd of ~2 μM and confirmed inhibition by heparin-derived tetrasaccharide. In renal tissue, MASP-2 partially colocalized with agrin and heparan sulfate, but not with activated C3, suggesting docking, storage, and potential inactivation of MASP-2 by heparan sulfate in basement membranes. Our data show that highly sulfated GAGs mediated inhibition of all three complement pathways, whereas short heparin- and heparan sulfate-derived oligosaccharides selectively blocked the lectin pathway via MASP-2 inhibition. Binding of MASP-2 to immobilized heparan sulfate/heparin and partial co-localization of agrin/heparan sulfate with MASP, but not C3b, might suggest that heparan sulfate proteoglycans act as a docking platform for MASP-2 and possibly prevent the lectin pathway from activation.
众所周知,肝素和其他糖胺聚糖(GAGs)可抑制补体激活。然而,尚不清楚 GAGs 的分级和/或修饰是否可提供补体系统的特定途径抑制。因此,我们评估了 GAG 文库及其衍生物对补体系统的功能途径特异性抑制作用,包括 MASP 特异性 C4 沉积测定。通过表面等离子体共振、ELISA 和肾组织评估人 MASP-2 与硫酸乙酰肝素/肝素的相互作用。补体途径特异性测定表明,高度硫酸化的 GAG 抑制补体的所有三个途径。肝素和硫酸乙酰肝素衍生的小寡糖是凝集素途径(LP)的选择性抑制剂。这些小寡糖对 ficolin-3 介导的 LP 激活具有相同的抑制作用,不能抑制 MBL 与甘露聚糖的结合,但抑制 MASP 介导的 C4 裂解。六硫酸和五硫酸四糖在功能 LP 测定以及 MASP 介导的 C4 测定中均为最小的 MASP 抑制剂。表面等离子体共振显示 MASP-2 与肝素和硫酸乙酰肝素结合,揭示高 Kon 和 Koff 速率导致 Kd 值约为 2 μM,并证实肝素衍生的四糖抑制作用。在肾组织中,MASP-2 与 agrin 和硫酸乙酰肝素部分共定位,但不与活化的 C3 共定位,表明 MASP-2 在基底膜中通过硫酸乙酰肝素结合、储存和潜在失活。我们的数据表明,高度硫酸化的 GAG 介导所有三种补体途径的抑制作用,而短的肝素和硫酸乙酰肝素衍生的寡糖通过 MASP-2 抑制选择性阻断凝集素途径。MASP-2 与固定化硫酸乙酰肝素/肝素的结合以及 agrin/硫酸乙酰肝素与 MASP 的部分共定位,但不与 C3b 共定位,可能表明硫酸乙酰肝素蛋白聚糖作为 MASP-2 的对接平台,并可能防止凝集素途径激活。